Remove Disease Remove Drug Trials Remove Treatment Remove Trials
article thumbnail

AI-discovered ALS drug trial uses unique remote monitoring

Drug Discovery World

Verge Genomics has initiated a Phase Ib proof-of-concept study for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS) with VRG50635. ALS is a progressive neurodegenerative disease that affects motor neuron cells in the brain and spinal cord causing progressive paralysis of voluntary muscles.

article thumbnail

Patients achieve 19% weight loss in obesity drug trial

Drug Discovery World

New data from Boehringer Ingelheim and Zealand Pharma has demonstrated superior efficacy with survodutide (also known as BI 456906) versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment. Current treatments for obesity mainly focus on weight loss by reducing energy intake.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scleroderma drug trial shows up to 60% improvement

Drug Discovery World

Biotechnology company Certa Therapeutics has revealed positive Phase II clinical trial data for FT011 in patients with scleroderma. Treatment with FT011 for 12 weeks resulted in a clinically meaningful improvement in 60% of patients treated with FT011 400mg and 20% of patients in the FT011 200mg group compared with 10% in the placebo group.

article thumbnail

Phase III pulmonary fibrosis drug trial fails

Drug Discovery World

Bellerophon Therapeutics has announced it will close its Phase III study of INOpulse, its treatment for fibrotic Interstitial Lung Disease (fILD), after the trail failed to meet its primary endpoint. The post Phase III pulmonary fibrosis drug trial fails appeared first on Drug Discovery World (DDW).

article thumbnail

First patient dosed in ulcerative colitis drug trial

Drug Discovery World

A Phase I clinical trial has begun evaluating Direct Biologics’ ExoFlo for the treatment of patients with medically refractory ulcerative colitis (UC). Direct Biologics uses extracellular vesicles (EVs) derived from bone marrow mesenchymal stem cells (MSCs) to address multiple disease indications.

article thumbnail

Six advances in drug discovery for MND / ALS

Drug Discovery World

Ahead of Motor Neurone Disease (MND) Awareness Day on 21 June, we take a look back over the latest developments in the treatment of MND and amyotrophic lateral sclerosis (ALS). This Phase II clinical trial of drug candidate NX210c in patients with ALS is the first to target the integrity of the blood brain barrier (BBB).

article thumbnail

Integration of AI in imaging clinical trials 

Drug Discovery World

Sophie Winandy , Executive Director of Medical Imaging at ICON explores the benefits of AI and how it can be integrated throughout medical imaging within clinical trials. This can lead to generation of more objective endpoints that might lead to a better assessment of treatment efficacy.